Navigation Links
Genstruct's Andrea Matthews Selected for Mass High Tech's 'People to Watch Under 30'
Date:10/9/2007

CAMBRIDGE, Mass., Oct. 9 /PRNewswire/ -- Genstruct Inc., a biotechnology company translating the complexity of human biology to develop new successful therapeutics, today announced that Andrea Matthews (age 25), manager of its Scientific Programs, was selected by Mass High Tech for its "People to Watch Under 30."

"We are proud to have a young, successful individual like Andrea as part of our team," said Dr. Keith O. Elliston, president and CEO at Genstruct. "She has been a go-getter ever since she started at Genstruct during college. With her strong business, technology and scientific acumen, Andrea serves as a valued translator between our scientific and development teams. She not only shows significant initiative in advancing her career, but also excels in her personal life by volunteering to help Cambridge-area youth and competing in triathlons."

Ms. Matthews received her B.A. cum laude in biochemistry and molecular biology from Boston University in 2004. As an undergraduate summer student, she began working at Genstruct as the first full-time female employee for the company and the youngest by more than 10 years.

In her role as the manager of Scientific Programs at Genstruct, Ms. Matthews drives the progress of scientific and technology development for the company by prioritizing and managing requests across all of its pharmaceutical research projects. During her four years at Genstruct, she has presented scientific information and successfully gone head-to-head with scientists with more than 20 years of experience.

About Genstruct

Founded in 2002, Genstruct is a biotechnology company focused on elucidating the complexity of biology for the development of successful therapeutics. By modeling the components within the whole biological system, Genstruct delivers a deep molecular understanding of diseases and drug action, as well as mechanistic biomarkers to accelerate drug discovery and development programs. Genstruct engages in internal discovery and external development partnerships with top tier pharmaceutical companies, which apply systems biology in the areas of oncology, metabolic disorders, cardiovascular diseases and inflammation. The privately held company is based in Cambridge, Mass. For more information, please visit http://www.genstruct.com.

Genstruct and the Genstruct logo are registered trademarks and Molecular Epistemics, Knowledge Assembly, and Epistemics Engine are trademarks of Genstruct, Inc. All other trademarks or registered trademarks are properties of their respective owners.

Contact:

Karen Higgins

A & E Communications for Genstruct

(610) 831-5723

khiggins@aandecomm.com


'/>"/>
SOURCE Genstruct Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. San Diego firm selected for Madison Wi-Fi project
2. Milwaukee-based eFilm software selected by InSight Health, announces Workstation upgrade
3. Berbee Selected by Microsoft as Featured Speaker for New Product Launch
4. Can sales outsourcing grow Wisconsin biotechs?
5. Wisconsin biotechs plan Japan trade mission
6. Madison biotechs get Commerce grants
7. Midwest shares in stock-market bloodshed as biotechs falter
8. Technology helps but the best way to reduce Sarbox cost is with people
9. Age of empowered individuals: People power behind robust computing
10. Two-week notices: People are still concerned
11. Power for the people
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... AMRI, a global ... industries to improve patient outcomes and quality of life, will now be offering ... being attributed to new regulatory requirements for all new drug products, including the ...
(Date:10/11/2017)... ... October 11, 2017 , ... Personal eye wash is a basic first aid supply for any ... So which eye do you rinse first if a dangerous substance enters both eyes? It’s ... Wash with its unique dual eye piece. , “Whether its dirt and debris, or ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. 11, ... Research, London (ICR) and University of ... SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma (MM), ... nine . The University of Leeds ... funded by Myeloma UK, and ICR will perform the testing ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... San Diego-based ... of its corporate rebranding initiative announced today. The bold new look is part ... as the company moves into a significant growth period. , It will also expand ...
Breaking Biology Technology:
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/30/2017)... 30, 2017 Trends, opportunities and forecast in ... by technology (fingerprint, AFIS, iris recognition, facial recognition, hand ... by end use industry (government and law enforcement, commercial ... banking, and others), and by region ( North ... Asia Pacific , and the Rest of ...
(Date:3/27/2017)... ROCKVILLE CENTRE, N.Y. , March 27, 2017 ... by Healthcare Information and Management Systems Society (HIMSS) ... Analytics Outpatient EMR Adoption Model sm . In ... top 12% of U.S. hospitals using an electronic ... recognized CHS for its high level of EMR ...
Breaking Biology News(10 mins):